Expression and prognostic value of IL-6 and β-catenin in oral squamous cell carcinoma

doi:10.19439/j.sjos.2023.03.012

Abstract

Abstract: PURPOSE: To investigate the expression of interleukin-6 (IL-6) and β-catenin in oral squamous cell carcinoma (OSCC) and its clinicopathological significance. METHODS: The serum IL-6 concentration in 110 OSCC patients and 109 healthy controls were determined by chemiluminescence analysis. IL-6 and β-catenin expression levels in 68 tumor specimens of OSCC patients undergoing surgical treatment and 6 normal mucosal tissues were determined by immunohistochemistry method. The correlation between IL-6 and β-catenin and clinicopathological parameters and their prognostic value were analyzed. SPSS 22.0 software package was used for data analysis. RESULTS: Chemiluminescence method showed that the serum IL-6 content of OSCC patients was significantly increased (P<0.001). Immunohistochemical results demonstrated that high expression of IL-6 in OSCC tissues was remarkably associated with cervical lymph node metastasis(P=0.017), pathological differentiation(P=0.014), recurrence and distant metastasis (P=0.048). OSCC patients with high IL-6 expression showed a poor prognosis by Kaplan-Meier survival analysis. Multivariate Cox regression analysis showed that high expression of IL-6 was an independent risk factor affecting the prognosis of patients with OSCC(P<0.05). β-catenin hyperexpression was associated with pathological differentiation(P=0.006) and overall poor survival in OSCC patients. Spearman correlation analysis showed a positive correlation between IL-6 and β-catenin expression in OSCC (P<0.001). CONCLUSIONS: Serum IL-6 is expected to be a biomarker for detection of OSCC, and IL-6 and β-catenin expression in tumour tissues can be used as markers to evaluate the poor prognosis of OSCC.

Key words: Oral squamous cell carcinoma, IL-6, β-catenin, Prognosis

CLC Number:

R739.8

DONG Lin-sheng, TANG Jin, CHENG Wei, RAN Jing-xuan, LIU Zhao-bo, LI Ya-dong. Expression and prognostic value of IL-6 and β-catenin in oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2023, 32(3): 280-286.

References

[1] Mallela K, Shivananda S, Gopinath KS, et al.Oncogenic role of MiR-130a in oral squamous cell carcinoma[J]. Sci Rep, 2021, 11(1): 7787-7800.
[2] Yang Z, Yan G, Zheng L, et al.YKT6, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration[J]. Oncoimmunology, 2021, 10(1): 1938890.
[3] Priyadarshini M, Maji S, Samal SK, et al.SARI inhibits growth and reduces survival of oral squamous cell carcinomas (OSCC) by inducing endoplasmic reticulum stress[J]. Life Sci, 2021, 287: 120141.
[4] Siegel RL, Miller KD, Fuchs HE, et al.Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[5] Jager A, Sleijfer S, Van Der Rijt CC. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?[J]. Eur J Cancer, 2008, 44(2): 175-181.
[6] Mirkeshavarz M, Ganjibakhsh M, Aminishakib P, et al.Interleukin-6 secreted by oral cancer- associated fibroblast accelerated VEGF expression in tumor and stroma cells[J]. Cell Mol Biol (Noisy-le-grand), 2017, 63(10): 131-136.
[7] Ren R, Yu J, Zhang Y, et al.Inflammation promotes progression of pancreatic cancer through WNT/β-Catenin pathway-dependent manner[J]. Pancreas, 2019, 48(8): 1003-1014.
[8] Paluszczak J.The significance of the dysregulation of canonical wnt signaling in head and neck squamous cell carcinomas[J]. Cells, 2020, 9(3): 723-743.
[9] Li Q, Ye L, Zhang X, et al.FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling[J]. Cancer Lett, 2017, 402: 166-176.
[10] Zhang S, Yin C.BCL-3 and β-catenin signaling and tumor staging in colorectal cancer[J]. Cell Mol Biol (Noisy-le-grand), 2020, 66(5): 87-91.
[11] Yuan J, Xing H, Li Y, et al.EPB41 suppresses the Wnt/β-catenin signaling in non-small cell lung cancer by sponging ALDOC[J]. Cancer Lett, 2021, 499: 255-264.
[12] Quinn HM, Vogel R, Popp O, et al.YAP and β-Catenin cooperate to drive oncogenesis in basal breast cancer[J]. Cancer Res, 2021, 81(8): 2116-2127.
[13] Kim B, Seo Y, Kwon J H, et al.IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor[J]. Mol Carcinog, 2021, 60(3): 188-200.
[14] Chen X, Chen F, Ren Y, et al.IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2[J]. J Cancer Res Clin Oncol, 2019, 145(6): 1471-1484.
[15] Che D, Zhang S, Jing Z, et al.Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE(2)/β-catenin signalling pathway[J]. Mol Immunol, 2017, 90: 197-210.
[16] Zhuang M, Ding X, Song W, et al.Correlation of IL-6 and JAK2/STAT3 signaling pathway with prognosis of nasopharyngeal carcinoma patients[J]. Aging (Albany NY), 2021, 13(12): 16667-16683.
[17] Babiuch K, Kusnierz-cabala B, Kesek B, et al. Evaluation of proinflammatory, NF-kappaB dependent cytokines: IL-1α, IL-6, IL-8, and TNF-α in tissue specimens and saliva of patients with oral squamous cell carcinoma and oral potentially malignant disorders[J]. J Clin Med, 2020, 9(3): 867-883.
[18] Greco A, De Virgilio A, Rizzo MI, et al.The prognostic role of E-cadherin and β-catenin overexpression in laryngeal squamous cell carcinoma[J]. Laryngoscope, 2016, 126(4): 148-155.
[19] Dikova V, Jantus-lewintre E, Bagan J. Potential non-invasive biomarkers for early diagnosis of oral squamous cell carcinoma[J]. J Clin Med, 2021, 10(8): 1658-1673.
[20] Rezaei F, Mohammadi H, Heydari M, et al.Association between IL-8 (-251T/A) and IL-6 (-174G/C) polymorphisms and oral cancer susceptibility: a systematic review and meta-analysis[J]. Medicina (Kaunas), 2021, 57(5): 405-421.
[21] Guo H, Jiang W, Huang S, et al.Serum exosome-derived biomarkers for the early detection of oral squamous cell carcinoma[J]. Mol Cell Biochem, 2021, 476(12): 4435-4447.
[22] Rezaei F, Mozaffari HR, Tavasoli J, et al.Evaluation of serum and salivary interleukin-6 and interleukin-8 levels in oral squamous cell carcinoma patients: systematic review and meta-analysis[J]. J Interferon Cytokine Res, 2019, 39(12): 727-739.
[23] Kim HW, Lee JC, Paik KH, et al.Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern[J]. Medicine (Baltimore), 2017, 96(5): e5926.
[24] Chen CJ, Sung WW, Lin YM, et al.Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma[J]. PLoS One, 2012, 7(11): e50104.
[25] Chen MF, Chen PT, Lu MS, et al.IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus[J]. Mol Cancer, 2013, 12: 26-37.
[26] Tsai MS, Chen WC, Lu CH, et al.The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling[J]. Oral Oncol, 2019, 91: 47-55.
[27] Huang Q, Zhang Z, Liao Y, et al.17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression[J]. J Exp Clin Cancer Res, 2018, 37(1): 133-140.
[28] Zargaran M.Alternation of β-catenin and CD44s immunoexpression in different histopathological grades of oral squamous cell carcinoma[J]. Asian Pac J Cancer Prev, 2020, 21(5): 1181-1185.
[29] Krishnamurthy N, Kurzrock R.Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors[J]. Cancer Treat Rev, 2018, 62: 50-60.
[30] Zhang H, Sun W, Qiao G, et al.The expression of tripartite motif protein 36 and β-Catenin correlates with the prognosis of esophageal cancer[J]. Gastroenterol Res Pract, 2020: 7641761.
[31] Liu S, Ding G, Zhou Z, et al.β-catenin-driven adrenocortical carcinoma is characterized with immune exclusion[J]. Onco Targets Ther, 2018, 11: 2029-2036.
[32] Roy S, Kar M, Roy S, et al.Role of beta-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma[J]. Cell Oncol (Dordr), 2018, 41(2): 185-200.
[33] Pramanik KC, Fofaria NM, Gupta P, et al.Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3[J]. Oncotarget, 2015, 6(13): 11561-11574.
[34] Zhang GJ, Li LF, Yang GD, et al.MiR-92a promotes stem cell-like properties by activating Wnt/β-catenin signaling in colorectal cancer[J]. Oncotarget, 2017, 8(60): 101760-101770.
[35] Nguyen MLT, Bui KC, Scholta T, et al.Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma[J]. J Gastroenterol Hepatol, 2021, 36(5): 1334-1345.
[36] Gao S, Hu J, Wu X, et al.PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent activation of Wnt/beta-catenin signaling pathway[J]. Biomed Pharmacother, 2018, 108: 618-624.